<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03305419</url>
  </required_header>
  <id_info>
    <org_study_id>205184</org_study_id>
    <secondary_id>2017-002662-45</secondary_id>
    <nct_id>NCT03305419</nct_id>
  </id_info>
  <brief_title>A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy Subjects</brief_title>
  <official_title>A Single-centre, Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2982772 in Repeat Oral Doses in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerability and PK of GSK2982772, in repeat&#xD;
      oral doses in healthy subjects. This study is being conducted to support administration of&#xD;
      higher dose levels of GSK2982772 than initially studied in the First Time in Human (FTiH)&#xD;
      study. This study will also assess the impact of food during the repeat doses of GSK2982772.&#xD;
      This will be a two part study; Part A and Part B. Part A (cohort 1) - single ascending dose,&#xD;
      randomized, placebo-controlled, 3-way crossover. Part B (cohorts 2, 3, 4 and 5) - repeat&#xD;
      dose, randomized, placebo-controlled, sequential-group. Subjects will be randomized in 3:1&#xD;
      ratio to receive GSK2982772 or placebo in crossover manner on Day 1 of each of the three&#xD;
      periods in Part A. Subjects will be randomized in 3:1 ratio to receive GSK2982772 or placebo&#xD;
      in sequential groups for 14 days in cohort 2 of Part B and in 9:5 ratio to receive GSK2982772&#xD;
      or placebo in sequential groups for 14 days in cohorts 3, 4 and 5 of Part B. Approximately 66&#xD;
      subjects will be included in this study. The study duration, including screening and&#xD;
      follow-up, will not be expected to exceed 13 weeks for Part A and 8 weeks for Part B.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 11, 2017</start_date>
  <completion_date type="Actual">October 15, 2018</completion_date>
  <primary_completion_date type="Actual">October 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This study will consist of two parts; Part A and Part B. Part A will be a 3-way crossover design and Part B will be a sequential-group design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This will be a double-blind study. Subjects and investigator will be masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Adverse Events (AEs) and Serious AEs (SAEs): Part A</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study subjects, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment will be categorized as SAE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With AEs and SAEs: Part B</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment were categorized as SAE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Worst Case Clinical Chemistry Parameters by Potential Clinical Importance Criteria: Part A</measure>
    <time_frame>Up to Week 9</time_frame>
    <description>Blood samples were collected from participants for the analysis of following clinical chemistry parameters: alanine amino transferase (ALT), albumin, alkaline phosphatase, aspartate amino transferase (AST), calcium, creatinine, glucose, potassium, sodium and total bilirubin. PCI ranges were &gt;=2 times Upper Limit of Normal (ULN) units per liter (U/L) for ALT, &lt;30 grams per liter (g/L) for albumin, &gt;=2 times ULN U/L for alkaline phosphatase, &gt;=2 times ULN U/L for AST, &lt;2 or &gt;2.75 millimoles per liter (mmol/L) for calcium, &gt;44.2 micromoles per liter (µmol/L) for creatinine, &lt;3 or &gt;9 mmol/L for glucose, &lt;3 or &gt;5.5 mmol/L for potassium, &lt;130 or &gt;150 mmol/L for sodium and &gt;=1.5 times ULN for total bilirubin. Participants were counted in the worst case category that their value changed to low, normal or high. If values were unchanged (example: High to High), or whose value became normal, were recorded in 'No Change' category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Worst Case Clinical Chemistry Parameters by Potential Clinical Importance Criteria: Part B</measure>
    <time_frame>Up to Week 4</time_frame>
    <description>Blood samples were collected from participants for the analysis of following clinical chemistry parameters: ALT, albumin, alkaline phosphatase, AST, calcium, creatinine, glucose, potassium, sodium and total bilirubin. PCI ranges were &gt;=2 times ULN U/L for ALT, &lt;30 g/L for albumin, &gt;=2 times ULN U/L for alkaline phosphatase, &gt;=2 times ULN U/L for AST, &lt;2 or &gt;2.75 mmol/L for calcium, &gt;44.2 µmol/L for creatinine, &lt;3 or &gt;9 mmol/L for glucose, &lt;3 or &gt;5.5 mmol/L for potassium, &lt;130 or &gt;150 mmol/L for sodium and &gt;=1.5 times ULN for total bilirubin. Participants were counted in the worst case category that their value changed to low, normal or high. If values were unchanged (example: High to High), or whose value became normal, were recorded in 'No Change' category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Worst Case Hematology Parameters by Potential Clinical Importance Criteria: Part A</measure>
    <time_frame>Up to Week 9</time_frame>
    <description>Blood samples were collected from participants for analysis of following hematology parameters; hematocrit, hemoglobin, lymphocytes, platelet count, total neutrophils and white blood cell (WBC) counts. PCI ranges were &gt;0.54 or &lt; 0.075 proportion of red blood cells (RBC) in blood for hematocrit, &lt;25 or &gt;180 g/L for hemoglobin, 0.8 x10^9 cells/L for lymphocytes, &lt;1.5 x10^9 cells/L for neutrophils, &lt;100 or &gt;550 x10^9 cells/L for platelets and &lt;3 or 20&gt; x 10^9 cells per liter WBC. Participants were counted in the worst case category that their value changed to low, normal or high. If values were unchanged (example: High to High), or whose value became normal, were recorded in 'No Change' category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Worst Case Hematology Parameters by Potential Clinical Importance Criteria: Part B</measure>
    <time_frame>Up to Week 4</time_frame>
    <description>Blood samples were collected from participants for analysis of following hematology parameters; hematocrit, hemoglobin, lymphocytes, platelet count, total neutrophils and WBC counts. PCI ranges were &gt;0.54 or &lt; 0.075 proportion of RBC in blood for hematocrit, &lt;25 or &gt;180 g/L for hemoglobin, 0.8 x10^9 cells/L for lymphocytes, &lt;1.5 x10^9 cells/L for neutrophils, &lt;100 or &gt;550 x10^9 cells/L for platelets and &lt;3 or 20&gt; x 10^9 cells per liter WBC. Participants were counted in the worst case category that their value changed to low, normal or high. If values were unchanged (example: High to High), or whose value became normal, were recorded in 'No Change' category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Worst Case Urinalysis Results: Part A</measure>
    <time_frame>Up to Week 9</time_frame>
    <description>Urine samples were collected from participants for analysis of following parameters: cellular casts, granular casts, hyaline casts, RBC and WBC and were counted as cells per high-power field (cells/HPF). The number of participants with cells in urine has been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Worst Case Urinalysis Results: Part B</measure>
    <time_frame>Up to Week 4</time_frame>
    <description>Urine samples were collected from participants for analysis of following parameters: cellular casts, granular casts, hyaline casts, RBC and WBC and were counted as cells per high-power field (cells/HPF). The number of participants with cells in urine has been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Vital Signs: Part A</measure>
    <time_frame>Up to Week 9</time_frame>
    <description>Vital signs were measured in a supine position after 5 minutes rest. The PCI criteria for vital signs included: systolic blood pressure &lt;85 and &gt;160 millimeters of mercury [mmHg]), diastolic blood pressure &lt;45 mmHg and &gt;100 mmHg, heart rate &lt;40 and &gt;100 beats per minute, body temperature &lt;=35.5 and &gt;=37.8 degrees Celsius and respiration rate &lt;=8 and &gt;=20 breaths per minute. Data of participants with potential clinical importance has been reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Vital Signs: Part B</measure>
    <time_frame>Up to Week 4</time_frame>
    <description>Vital signs were measured in a supine position after 5 minutes rest. The PCI criteria for vital signs included: systolic blood pressure &lt;85 and &gt;160 mmHg, diastolic blood pressure &lt;45 mmHg and &gt;100 mmHg, heart rate &lt;40 and &gt;100 beats per minute, body temperature &lt;=35.5 and &gt;=37.8 degrees Celsius and respiration rate &lt;=8 and &gt;=20 breaths per minute. Data of participants with potential clinical importance has been reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram (ECG) Findings: Part A</measure>
    <time_frame>Up to Day 4</time_frame>
    <description>12-lead ECG's were obtained in the supine position after 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Clinically significant and not clinically significant abnormal ECG findings have been presented. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal ECG Findings: Part B</measure>
    <time_frame>Up to Week 4</time_frame>
    <description>12-lead ECG's were obtained in the supine position after 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Clinically significant and not clinically significant abnormal ECG findings have been presented. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours (AUC[0-24]) Following TID Dosing of GSK2982772: Part A</measure>
    <time_frame>Pre-dose, 20, 40minutes, 1 hour, 1hr 30min, 2, 3, 5, 7hour, 7hr 20min,and 7hr 40 min, 8hr, 8hr 30min, 9hr, 10hr, 12hr, 14hr, 14hr 20min, 14hr 40 min, 15hr, 15hr 30min, 16hr, 17hr, 19hr, 22hr, 24hours post dose on Day1</time_frame>
    <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24) Following BID Dosing of GSK2982772: Part A</measure>
    <time_frame>Pre-dose, 20min, 40min, 1hr, 1hr 30min, 2hr, 3hr, 4hr, 6hr, 8hr, 10hr, 12hr, 12hr 20min, 12hr 40min, 13hr, 13hr 30min, 14hr, 15hr, 16hr, 19hr, 22hr, 24hr post dose on Day 1.</time_frame>
    <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC[0-24] Following TID Dosing of GSK2982772: Part B</measure>
    <time_frame>Pre-dose, 20, 40minutes, 1 hour, 1hr 30min, 2, 3, 5, 7hour, 7hr 20min,and 7hr 40 min, 8hr, 8hr 30min, 9hr, 10hr, 12hr, 14hr, 14hr 20min, 14hr 40 min, 15hr, 15hr 30min, 16hr, 17hr, 19hr, 22hr, 24hours post dose on Day14</time_frame>
    <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-7) Following TID Dosing of GSK2982772 : Part A</measure>
    <time_frame>Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, 7 hours on Day 1</time_frame>
    <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (7-14) Following TID Dosing of GSK2982772 : Part A</measure>
    <time_frame>7 hours, 7 hours 20 and 40 minutes, 8 hours, 8 hours 30 minutes, 9, 10, 12, 14 hours on Day 1</time_frame>
    <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (14-24) Following TID Dosing of GSK2982772 : Part A</measure>
    <time_frame>14 hours, 14 hours 20 and 40 minutes, 15 hours ,15 hours 30 minutes, 16, 19, 22 and 24 hours on Day 1</time_frame>
    <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-12) Following BID Dosing of GSK2982772 in Part A</measure>
    <time_frame>Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 4, 6, 8, 10 hours,12 hours on Day 1</time_frame>
    <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (12-24) Following BID Dosing of GSK2982772 in Part A</measure>
    <time_frame>12 hours, 12 hours 20 and 40 minutes, 13 and 13 hours 30 minutes, 14, 15, 16, 19, 22 and 24 hours on Day 1</time_frame>
    <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-7) Following TID Dosing of GSK2982772 in Part B</measure>
    <time_frame>Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, 7 hours on Days 1 and 14</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (7-14) Following TID Dosing of GSK2982772 in Part B</measure>
    <time_frame>7 and 7 hours 20 and 40 minutes, 8 and 8 hours 30 minutes, 9, 10, 12, 14 hours on Day 14</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (14-24) Following TID Dosing of GSK2982772 in Part B</measure>
    <time_frame>14 hours, 14 hours 20 minutes, 14 hours 40 minutes, 15 hours, 15 hours 30 minutes, 16, 17, 19, 22 and 24 hours on Day 14</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Drug Concentration Cmax (0-7) Following TID Dosing of GSK2982772 in Part A</measure>
    <time_frame>Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, and 7 hours post dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (7-14) Following TID Dosing of GSK2982772 in Part A</measure>
    <time_frame>7 hours, 7 hours 20 and 40 minutes, 8 and 8 hours 30 minutes, 9, 10, 12, 14 hours post dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (14-24) Following TID Dosing of GSK2982772 in Part A</measure>
    <time_frame>14 hours, 14 hours 20 and 40 minutes, 15 and 15 hours 30 minutes, 16, 19, 22 and 24 hours post dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (0-12) Following BID Dosing of GSK2982772 in Part A</measure>
    <time_frame>Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 4, 6, 8, 10 hours and 12 hours post dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (12-24) Following BID Dosing of GSK2982772 in Part A</measure>
    <time_frame>12 hours, 12 hours 20 and 40 minutes, 13 and 13 hours 30 minutes, 14, 15, 16, 19, 22 and 24 hours post dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (0-7) Following TID Dosing of GSK2982772 in Part B</measure>
    <time_frame>Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, 7 hours post dose on Days 1 and 14</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (7-14) Following TID Dosing of GSK2982772 in Part B</measure>
    <time_frame>7hours, 7 hours 20 and 40 minutes, 8 hours, 8 hours 30 minutes, 9, 10, 12, 14 hours on Day 14</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (14-24) Following TID Dosing of GSK2982772 in Part B</measure>
    <time_frame>14 hours, 14 hours 20 and 40 minutes, 15 hours, 15 hours 30 minutes, 16, 17, 19, 22 and 24 hours post dose on Day 14</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) (0-7) Following TID Dosing of GSK2982772 in Part A</measure>
    <time_frame>Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, and 7 hours post dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (7-14) Following TID Dosing of GSK2982772 in Part A</measure>
    <time_frame>7hours, 7 hours 20 and 40 minutes, 8 hours, 8 hours 30 minutes, 9, 10, 12, 14 hours post dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (14-24) Following TID Dosing of GSK2982772 in Part A</measure>
    <time_frame>14 hours, 14 hours 20 and 40 minutes, 15 hours, 15 hours 30 minutes, 16, 17, 19, 22 and 24 hours post dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (0-12) Following BID Dosing of GSK2982772 in Part A</measure>
    <time_frame>Pre-dose, 20 and 40 minutes, 1hour, 1 hour 30 minutes, 2, 3, 4, 6, 8, 10 hours and 12 hours post dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (12-24) Following BID Dosing of GSK2982772 in Part A</measure>
    <time_frame>12 hours, 12 hours 20 and 40 minutes, 13 hours, 13 hours 30 minutes, 14, 15, 16, 19, 22 and 24 hours post dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (0-7) Following TID Dosing of GSK2982772 Part B</measure>
    <time_frame>Pre-dose, 20 and 40 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 5, 7 hours post dose on Days 1 and 14</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (7-14) Following TID Dosing of GSK2982772 in Part B</measure>
    <time_frame>7hours and 7 hours 20 and 40 minutes, 8hours, 8 hours 30 minutes, 9, 10, 12, 14 hours post dose on Day 14</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (14-24) Following TID Dosing of GSK2982772 in Part B</measure>
    <time_frame>14hours, 14 hours 20 and 40 minutes, 15 hours and 15 hours 30 minutes, 16, 17, 19, 22 and 24 hours post dose on Day 14</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Trough Plasma Drug Concentration at 7 Hour (C7),Following TID Dosing of GSK2982772 in Part A</measure>
    <time_frame>7 hours post-dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Trough Plasma Drug Concentration at 14 Hours (C14) Following TID Dosing of GSK2982772 in Part A</measure>
    <time_frame>14 hours post-dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C24 Following TID Dosing of GSK2982772 in Part A</measure>
    <time_frame>24 hours post-dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C12 Following BID Dosing of GSK2982772 in Part A</measure>
    <time_frame>12 hours post-dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.&#xD;
Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C24 Following BID Dosing of GSK2982772 in Part A</measure>
    <time_frame>24 hours post-dose on Day 1</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C0 Following TID Dosing of GSK2982772 in Part B</measure>
    <time_frame>Pre-dose on Day 14</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C7 Following TID Dosing of GSK2982772 in Part B</measure>
    <time_frame>7 hours post-dose on Days 1 and 14</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C14 Following TID Dosing of GSK2982772 in Part B</measure>
    <time_frame>14 hours post-dose on Day 14</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C24 Following TID Dosing of GSK2982772 in Part B</measure>
    <time_frame>24 hours post-dose on Day 14</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC([0-7] Following TID Dosing of GSK2982772 in Fed State of Part B</measure>
    <time_frame>Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, 7 hours on Days 9 and 11</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (0-7) Following TID Dosing of GSK2982772 in Fed State of Part B</measure>
    <time_frame>Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, 7 hours on Days 9 and 11</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (0-7) Following TID Dosing of GSK2982772 in Fed State of Part B</measure>
    <time_frame>Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, 7 hours on Days 9 and 11</time_frame>
    <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Plasma 4 Beta-hydroxycholesterol to Cholesterol: Part B</measure>
    <time_frame>Pre-dose on Day 1 and 24 hours post first dose on Day 14</time_frame>
    <description>Blood samples were collected into EDTA tubes and processed to plasma for 4 beta-hydroxycholesterol and cholesterol. Ratio of 4 beta-hydroxycholesterol to cholesterol is presented</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence ABC in cohort 1: Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will be randomized to receive treatment sequence ABC in Part A; A= GSK2982772 120 mg TID, B= GSK2982772 240 mg TID, and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence ABP in cohort 1: Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will be randomized to receive treatment sequence ABP in Part A; A= GSK2982772 120 mg TID, B= GSK2982772 240 mg TID, and P= Placebo. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence APC in cohort 1: Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will be randomized to receive treatment sequence APC in Part A; A= GSK2982772 120 mg TID, P= Placebo and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence PBC in cohort 1: Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will be randomized to receive treatment sequence PBC in Part A; P= Placebo, B= GSK2982772 240 mg TID and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving GSK2982772 120 mg TID in cohort 2 : Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive GSK2982772 oral capsule with a dose of 120 mg TID for 14 days in Part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving GSK2982772 120 mg TID in cohort 3 : Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive GSK2982772 oral capsule with a dose of 120 mg TID for 14 days in Part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving GSK2982772 240 mg TID in cohort 4: Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive GSK2982772 oral capsule with a dose of 240 mg TID for 14 days in Part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving GSK2982772 360 mg BID in cohort 5: Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive GSK2982772 oral capsule with a dose of 360 mg BID for 14 days in Part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving placebo in cohort 2 : Part B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo oral capsule for 14 days in Part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving placebo in cohort 3 : Part B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo oral capsule for 14 days in Part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving placebo in cohort 4 : Part B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo oral capsule for 14 days in Part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving placebo in cohort 5: Part B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo oral capsule for 14 days in Part B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2982772 capsule</intervention_name>
    <description>GSK2982772 will be available as size 00, white, opaque capsule containing white to almost white Solid (120 mg maximum fill per capsule). It will be administered orally with water to receive total dose of 120 mg, 240 mg or 360 mg per randomization.</description>
    <arm_group_label>Subjects receiving GSK2982772 120 mg TID in cohort 2 : Part B</arm_group_label>
    <arm_group_label>Subjects receiving GSK2982772 120 mg TID in cohort 3 : Part B</arm_group_label>
    <arm_group_label>Subjects receiving GSK2982772 240 mg TID in cohort 4: Part B</arm_group_label>
    <arm_group_label>Subjects receiving GSK2982772 360 mg BID in cohort 5: Part B</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence ABC in cohort 1: Part A</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence ABP in cohort 1: Part A</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence APC in cohort 1: Part A</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence PBC in cohort 1: Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>Placebo will be available as size 00, white, opaque capsule containing white to almost white Solid. It will be administered orally with water.</description>
    <arm_group_label>Subjects receiving placebo in cohort 2 : Part B</arm_group_label>
    <arm_group_label>Subjects receiving placebo in cohort 3 : Part B</arm_group_label>
    <arm_group_label>Subjects receiving placebo in cohort 4 : Part B</arm_group_label>
    <arm_group_label>Subjects receiving placebo in cohort 5: Part B</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence ABC in cohort 1: Part A</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence ABP in cohort 1: Part A</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence APC in cohort 1: Part A</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence PBC in cohort 1: Part A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be 18 to 65 years of age inclusive, at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          -  Healthy as determined by the Investigator or medically qualified designee based on a&#xD;
             medical evaluation including medical history, physical examination, neurological&#xD;
             examination, laboratory tests and cardiac monitoring. A subject with a clinical&#xD;
             abnormality or laboratory parameter(s) which is/are not specifically listed in the&#xD;
             inclusion or exclusion criteria, outside the reference range for the population being&#xD;
             studied may be included only if the Investigator in consultation with the Medical&#xD;
             Monitor (if required) agree and document that the finding is unlikely to introduce&#xD;
             additional risk factors and will not interfere with the study procedures.&#xD;
&#xD;
          -  Body weight &gt;=50 kilograms (kg) and body mass index (BMI) within the range 19 - 30 kg&#xD;
             per square meter (kg/m^2) (inclusive).&#xD;
&#xD;
          -  A male subject with a female partner of reproductive potential must agree to use&#xD;
             contraception during the treatment period and for at least 90 days after the last dose&#xD;
             of study treatment and refrain from donating sperm during this period. A female&#xD;
             subject is eligible to participate if she is not pregnant, not breastfeeding, and at&#xD;
             least one of the following conditions applies: not a woman of childbearing potential&#xD;
             (WOCBP) or a WOCBP who agrees to follow the contraceptive guidance for a minimum of 28&#xD;
             days prior to the treatment period and for at least 30 days after the last&#xD;
             administration of study drug. A WOCBP using a hormonal method of highly effective&#xD;
             contraception must also agree to partner use of a male condom during the treatment&#xD;
             period and for at least 30 days after the last administration of study drug.&#xD;
&#xD;
          -  Capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of or current cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine, hematological, or neurological disorders capable of&#xD;
             significantly altering the absorption, metabolism, or elimination of drugs;&#xD;
             constituting a risk when taking the study treatment; or interfering with the&#xD;
             interpretation of data.&#xD;
&#xD;
          -  History of herpes zoster (shingles) reactivation.&#xD;
&#xD;
          -  Evidence of active or latent tuberculosis (TB) as documented by medical history and&#xD;
             examination, chest x-rays (posterior anterior and lateral), and TB testing: either a&#xD;
             positive tuberculin skin test (TST; defined as a skin induration &gt;5 millimeter (mm) at&#xD;
             48 to 72 hours, regardless of Bacillus Calmette-Guerin (BCG) or other vaccination&#xD;
             history) or a positive (not indeterminate) QuantiFERON-TB Gold test.&#xD;
&#xD;
          -  ALT &gt;1.5 times upper limit of normal (ULN).&#xD;
&#xD;
          -  Bilirubin &gt;1.5 times ULN (isolated bilirubin &gt;1.5 times ULN is acceptable if bilirubin&#xD;
             is fractionated and direct bilirubin &lt;35%).&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  ECG QT interval corrected for heart rate (QTc) &gt;450 millisecond (msec).&#xD;
&#xD;
          -  History of serious or recurrent infections or has had an active infection within 14&#xD;
             days of receiving study medication.&#xD;
&#xD;
          -  History of diagnosis of obstructive sleep apnoea or significant respiratory disorder.&#xD;
             Childhood asthma that has fully resolved is permitted.&#xD;
&#xD;
          -  Part A: History of active suicidal ideation behavior (SIB) within the past 6 months or&#xD;
             any history of attempted suicide in a subject's lifetime.&#xD;
&#xD;
          -  History of current evidence of febrile seizures, epilepsy, convulsions, significant&#xD;
             head injury, or other significant neurologic conditions.&#xD;
&#xD;
          -  Past or intended use of over-the-counter or prescription medication, including herbal&#xD;
             medications, within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5&#xD;
             half-lives (whichever is the longest) prior to dosing.&#xD;
&#xD;
          -  Subject received a vaccine (either live attenuated or now-live) within 30 days prior&#xD;
             to randomization, or plans to receive a live attenuated vaccine within 30 days + 5&#xD;
             half-lives (32 days) of the last dose of study medication.&#xD;
&#xD;
          -  Participation in the study would result in loss of blood or blood products in excess&#xD;
             of 500 milliliters (mL) within a 56-day period.&#xD;
&#xD;
          -  Exposure to more than 4 new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  Presence of Hepatitis B surface antigen (HBsAg) at screening Positive Hepatitis C&#xD;
             antibody test result at screening.&#xD;
&#xD;
          -  Positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  Positive human immunodeficiency virus (HIV1 and 2) antibody test.&#xD;
&#xD;
          -  Regular use of known drugs of abuse.&#xD;
&#xD;
          -  Subjects with impaired renal function defined as Chronic Kidney Disease Epidemiology&#xD;
             Collaboration (CKS-EPI) Creatinine &gt; 1.6 mg/deciliter (mg/dL) with an age appropriate&#xD;
             glomerular filtration rate (GFR) &lt;= 60 (mL/minute/1.73 m^2) estimated by the Chronic&#xD;
             Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.&#xD;
&#xD;
          -  An elevated C-reactive protein (CRP) outside of the normal reference range.&#xD;
&#xD;
          -  Regular alcohol consumption within 6 months prior to the study defined as: For United&#xD;
             Kingdom (UK) - an average weekly intake of &gt;14 units for males and females. One unit&#xD;
             is equivalent to 8 grams (g) of alcohol: a half-pint (approximately 240 mL) of beer, 1&#xD;
             glass (125 mL) of wine or 1 (25 mL) measure of spirits.&#xD;
&#xD;
          -  Cotinine or carbon monoxide levels indicative of smoking or history or regular use of&#xD;
             tobacco- or nicotine-containing products within 6 months prior to screening.&#xD;
&#xD;
          -  Sensitivity to any of the study treatments, or components thereof, or drug or other&#xD;
             allergy that, in the opinion of the investigator or medical monitor, contraindicates&#xD;
             participation in the study.&#xD;
&#xD;
          -  Unwilling or unable to swallow multiple size 00 capsules as part of study&#xD;
             participation.&#xD;
&#xD;
        PART B Specific exclusion criteria:&#xD;
&#xD;
          -  History of SIB as measured using the Columbia Suicide Severity Rating Scale (C-SSRS)&#xD;
             or a history of attempted suicide.&#xD;
&#xD;
          -  A positive anti-nuclear antibody (ANA) outside of the normal reference range.&#xD;
&#xD;
          -  Fasting total cholesterol &gt;=300 mg/dL or triglycerides &gt;=250 mg/dL.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2GG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 4, 2017</study_first_submitted>
  <study_first_submitted_qc>October 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2017</study_first_posted>
  <results_first_submitted>October 11, 2019</results_first_submitted>
  <results_first_submitted_qc>October 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2019</results_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crossover</keyword>
  <keyword>Sequential</keyword>
  <keyword>GSK2982772</keyword>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Healthy subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT03305419/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT03305419/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study consisted of two parts; part A was single ascending dose, 3-way crossover and part B was repeat dose, sequential assignment which investigated the safety, tolerability, and pharmacokinetics of GSK2982772, in healthy participants.</recruitment_details>
      <pre_assignment_details>A total of 62 participants (15 in Part A and 47 in Part B) were enrolled in the study. Participants were not enrolled into the GSK2982772 360 milligram (mg) twice daily (BID) arm of Part B as one participant in the 360 mg BID dose level in Part A exceeded the maximum concentration (Cmax) stopping criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A:GSK2982772 120 mg TID/240 mg TID/360 mg BID</title>
          <description>Participants received oral capsule of 120 mg GSK2982772 TID in treatment period 1 followed by 240 mg TID in treatment period 2 followed by 360 mg BID in treatment period 3. The treatment periods were separated by a washout period of at least 7 days.</description>
        </group>
        <group group_id="P2">
          <title>Part A:GSK2982772 120 mg TID/240 mg TID/Placebo</title>
          <description>Participants received oral capsule of 120 mg GSK2982772 TID in treatment period 1 followed by 240 mg TID in treatment period 2 followed by matching Placebo in treatment period 3. The treatment periods were separated by a washout period of at least 7 days.</description>
        </group>
        <group group_id="P3">
          <title>Part A:GSK2982772 120 mg TID/Placebo/GSK2982772 360 mg BID</title>
          <description>Participants received oral capsule of 120 mg GSK2982772 TID in treatment period 1 followed by matching Placebo in treatment period 2 followed by 360 mg GSK2982772 BID in treatment period 3. The treatment periods were separated by a washout period of at least 7 days.</description>
        </group>
        <group group_id="P4">
          <title>Part A:Placebo/GSK2982772 240 mg TID/360 mg BID</title>
          <description>Participants received oral capsule of matching Placebo in treatment period 1 followed by 240 mg GSK2982772 TID in treatment period 2 followed by 360 mg GSK2982772 BID in treatment period 3. The treatment periods were separated by a washout period of at least 7 days.</description>
        </group>
        <group group_id="P5">
          <title>Part B:Placebo</title>
          <description>Participants received matching oral placebo capsule to GSK2928772 for 14 days.</description>
        </group>
        <group group_id="P6">
          <title>Part B:GSK2982772 120 mg TID</title>
          <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
        </group>
        <group group_id="P7">
          <title>Part B:GSK2982772 240 mg TID</title>
          <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
        </group>
        <group group_id="P8">
          <title>Part B:GSK2982772 360 mg BID</title>
          <description>Participants were planned to receive GSK2982772 oral capsule at a dose of 360 mg BID for 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A Period 1 (1Day) + Washout (7days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part A Period 2 (1Day) + Washout (7days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3">1 participant was added to GSK2982772 120 mg TID/240 mg TID/Placebo arm</participants>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part A Period 3 (1Day) + Washout (7days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3">2 participants were added to GSK2982772 120 mg TID/240 mg TID/360 mg BID arm after Washout Period.</participants>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="20"/>
                <participants group_id="P7" count="13"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants were not enrolled into the GSK2982772 360 mg BID of Part B as one participant in the 360 mg BID dose level in Part A exceeded the maximum concentration (Cmax) stopping criteria.</population>
      <group_list>
        <group group_id="B1">
          <title>Part A:GSK2982772 120 mg TID/240 mg TID/360 mg BID</title>
          <description>Participants received oral capsule of 120 mg GSK2982772 three times a day in treatment period 1 followed by 240 mg TID in treatment period 2 followed by 360 mg BID in treatment period 3. The treatment periods were separated by a washout period of at least 7 days.</description>
        </group>
        <group group_id="B2">
          <title>Part A:GSK2982772 120 mg TID/240 mg TID/Placebo</title>
          <description>Participants received oral capsule of 120 mg GSK2982772 TID in treatment period 1 followed by 240 mg TID in treatment period 2 followed by matching Placebo in treatment period 3. The treatment periods were separated by a washout period of at least 7 days.</description>
        </group>
        <group group_id="B3">
          <title>Part A:GSK2982772 120 mg TID/Placebo/GSK2982772 360 mg BID</title>
          <description>Participants received oral capsule of 120 mg GSK2982772 TID in treatment period 1 followed by matching Placebo in treatment period 2 followed by 360 mg GSK2982772 BID in treatment period 3. The treatment periods were separated by a washout period of at least 7 days.</description>
        </group>
        <group group_id="B4">
          <title>Part A:Placebo/GSK2982772 240 mg TID/360 mg BID</title>
          <description>Participants received oral capsule of matching Placebo in treatment period 1 followed by 240 mg GSK2982772 TID in treatment period 2 followed by 360 mg GSK2982772 BID in treatment period 3. The treatment periods were separated by a washout period of at least 7 days.</description>
        </group>
        <group group_id="B5">
          <title>Part B:Placebo</title>
          <description>Participants received matching oral placebo capsule to GSK2928772 for 14 days.</description>
        </group>
        <group group_id="B6">
          <title>Part B:GSK2982772 120 mg TID</title>
          <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
        </group>
        <group group_id="B7">
          <title>Part B:GSK2982772 240 mg TID</title>
          <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
        </group>
        <group group_id="B8">
          <title>Part B:GSK2982772 360 mg TID</title>
          <description>Participants received GSK2982772 oral capsule at a dose of 360 mg TID for 14 days.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="14"/>
            <count group_id="B6" value="20"/>
            <count group_id="B7" value="13"/>
            <count group_id="B8" value="0"/>
            <count group_id="B9" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.2" spread="9.04"/>
                    <measurement group_id="B2" value="42.5" spread="9.95"/>
                    <measurement group_id="B3" value="59.0" spread="3.61"/>
                    <measurement group_id="B4" value="49.0" spread="10.00"/>
                    <measurement group_id="B5" value="39.1" spread="9.66"/>
                    <measurement group_id="B6" value="43.3" spread="10.87"/>
                    <measurement group_id="B7" value="38.6" spread="11.03"/>
                    <measurement group_id="B9" value="45.25" spread="9.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Japanese Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - White/Caucasian/European Herit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B9" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Adverse Events (AEs) and Serious AEs (SAEs): Part A</title>
        <description>An AE is any untoward medical occurrence in a clinical study subjects, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment will be categorized as SAE.</description>
        <time_frame>Up to Day 14</time_frame>
        <population>Safety population. Safety population consists of all randomized participants who take at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:Placebo</title>
            <description>Participants received matching oral placebo capsule to GSK2928772</description>
          </group>
          <group group_id="O2">
            <title>Part A:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID</description>
          </group>
          <group group_id="O3">
            <title>Part A:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID</description>
          </group>
          <group group_id="O4">
            <title>Part A:GSK2982772 360 mg BID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 360 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events (AEs) and Serious AEs (SAEs): Part A</title>
          <description>An AE is any untoward medical occurrence in a clinical study subjects, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment will be categorized as SAE.</description>
          <population>Safety population. Safety population consists of all randomized participants who take at least 1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With AEs and SAEs: Part B</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment were categorized as SAE.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>Safety population. GSK2982772 360 mg BID was not started in Part B as one participant in GSK2982772 360 mg BID of Part A exceeded the Cmax stopping criteria</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:Placebo</title>
            <description>Participants received matching oral placebo capsule to GSK2928772 for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B:GSK2982772 360 mg BID</title>
            <description>Participants were planned to receive GSK2982772 oral capsule at a dose of 360 mg BID for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With AEs and SAEs: Part B</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment were categorized as SAE.</description>
          <population>Safety population. GSK2982772 360 mg BID was not started in Part B as one participant in GSK2982772 360 mg BID of Part A exceeded the Cmax stopping criteria</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Worst Case Clinical Chemistry Parameters by Potential Clinical Importance Criteria: Part A</title>
        <description>Blood samples were collected from participants for the analysis of following clinical chemistry parameters: alanine amino transferase (ALT), albumin, alkaline phosphatase, aspartate amino transferase (AST), calcium, creatinine, glucose, potassium, sodium and total bilirubin. PCI ranges were &gt;=2 times Upper Limit of Normal (ULN) units per liter (U/L) for ALT, &lt;30 grams per liter (g/L) for albumin, &gt;=2 times ULN U/L for alkaline phosphatase, &gt;=2 times ULN U/L for AST, &lt;2 or &gt;2.75 millimoles per liter (mmol/L) for calcium, &gt;44.2 micromoles per liter (µmol/L) for creatinine, &lt;3 or &gt;9 mmol/L for glucose, &lt;3 or &gt;5.5 mmol/L for potassium, &lt;130 or &gt;150 mmol/L for sodium and &gt;=1.5 times ULN for total bilirubin. Participants were counted in the worst case category that their value changed to low, normal or high. If values were unchanged (example: High to High), or whose value became normal, were recorded in 'No Change' category.</description>
        <time_frame>Up to Week 9</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:Placebo</title>
            <description>Participants received matching oral placebo capsule to GSK2928772</description>
          </group>
          <group group_id="O2">
            <title>Part A:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID</description>
          </group>
          <group group_id="O3">
            <title>Part A:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID</description>
          </group>
          <group group_id="O4">
            <title>Part A:GSK2982772 360 mg BID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 360 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Worst Case Clinical Chemistry Parameters by Potential Clinical Importance Criteria: Part A</title>
          <description>Blood samples were collected from participants for the analysis of following clinical chemistry parameters: alanine amino transferase (ALT), albumin, alkaline phosphatase, aspartate amino transferase (AST), calcium, creatinine, glucose, potassium, sodium and total bilirubin. PCI ranges were &gt;=2 times Upper Limit of Normal (ULN) units per liter (U/L) for ALT, &lt;30 grams per liter (g/L) for albumin, &gt;=2 times ULN U/L for alkaline phosphatase, &gt;=2 times ULN U/L for AST, &lt;2 or &gt;2.75 millimoles per liter (mmol/L) for calcium, &gt;44.2 micromoles per liter (µmol/L) for creatinine, &lt;3 or &gt;9 mmol/L for glucose, &lt;3 or &gt;5.5 mmol/L for potassium, &lt;130 or &gt;150 mmol/L for sodium and &gt;=1.5 times ULN for total bilirubin. Participants were counted in the worst case category that their value changed to low, normal or high. If values were unchanged (example: High to High), or whose value became normal, were recorded in 'No Change' category.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Worst Case Clinical Chemistry Parameters by Potential Clinical Importance Criteria: Part B</title>
        <description>Blood samples were collected from participants for the analysis of following clinical chemistry parameters: ALT, albumin, alkaline phosphatase, AST, calcium, creatinine, glucose, potassium, sodium and total bilirubin. PCI ranges were &gt;=2 times ULN U/L for ALT, &lt;30 g/L for albumin, &gt;=2 times ULN U/L for alkaline phosphatase, &gt;=2 times ULN U/L for AST, &lt;2 or &gt;2.75 mmol/L for calcium, &gt;44.2 µmol/L for creatinine, &lt;3 or &gt;9 mmol/L for glucose, &lt;3 or &gt;5.5 mmol/L for potassium, &lt;130 or &gt;150 mmol/L for sodium and &gt;=1.5 times ULN for total bilirubin. Participants were counted in the worst case category that their value changed to low, normal or high. If values were unchanged (example: High to High), or whose value became normal, were recorded in 'No Change' category.</description>
        <time_frame>Up to Week 4</time_frame>
        <population>Safety population. GSK2982772 360 mg BID of Part B was not started as one participant in GSK2982772 360 mg BID of Part A exceeded the Cmax stopping criteria</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:Placebo</title>
            <description>Participants received matching oral placebo capsule to GSK2928772 for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B:GSK2982772 360 mg BID</title>
            <description>Participants were planned to receive GSK2982772 oral capsule at a dose of 360 mg BID for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Worst Case Clinical Chemistry Parameters by Potential Clinical Importance Criteria: Part B</title>
          <description>Blood samples were collected from participants for the analysis of following clinical chemistry parameters: ALT, albumin, alkaline phosphatase, AST, calcium, creatinine, glucose, potassium, sodium and total bilirubin. PCI ranges were &gt;=2 times ULN U/L for ALT, &lt;30 g/L for albumin, &gt;=2 times ULN U/L for alkaline phosphatase, &gt;=2 times ULN U/L for AST, &lt;2 or &gt;2.75 mmol/L for calcium, &gt;44.2 µmol/L for creatinine, &lt;3 or &gt;9 mmol/L for glucose, &lt;3 or &gt;5.5 mmol/L for potassium, &lt;130 or &gt;150 mmol/L for sodium and &gt;=1.5 times ULN for total bilirubin. Participants were counted in the worst case category that their value changed to low, normal or high. If values were unchanged (example: High to High), or whose value became normal, were recorded in 'No Change' category.</description>
          <population>Safety population. GSK2982772 360 mg BID of Part B was not started as one participant in GSK2982772 360 mg BID of Part A exceeded the Cmax stopping criteria</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Worst Case Hematology Parameters by Potential Clinical Importance Criteria: Part A</title>
        <description>Blood samples were collected from participants for analysis of following hematology parameters; hematocrit, hemoglobin, lymphocytes, platelet count, total neutrophils and white blood cell (WBC) counts. PCI ranges were &gt;0.54 or &lt; 0.075 proportion of red blood cells (RBC) in blood for hematocrit, &lt;25 or &gt;180 g/L for hemoglobin, 0.8 x10^9 cells/L for lymphocytes, &lt;1.5 x10^9 cells/L for neutrophils, &lt;100 or &gt;550 x10^9 cells/L for platelets and &lt;3 or 20&gt; x 10^9 cells per liter WBC. Participants were counted in the worst case category that their value changed to low, normal or high. If values were unchanged (example: High to High), or whose value became normal, were recorded in 'No Change' category.</description>
        <time_frame>Up to Week 9</time_frame>
        <population>Safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:Placebo</title>
            <description>Participants received matching oral placebo capsule to GSK2928772</description>
          </group>
          <group group_id="O2">
            <title>Part A:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID</description>
          </group>
          <group group_id="O3">
            <title>Part A:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID</description>
          </group>
          <group group_id="O4">
            <title>Part A:GSK2982772 360 mg BID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 360 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Worst Case Hematology Parameters by Potential Clinical Importance Criteria: Part A</title>
          <description>Blood samples were collected from participants for analysis of following hematology parameters; hematocrit, hemoglobin, lymphocytes, platelet count, total neutrophils and white blood cell (WBC) counts. PCI ranges were &gt;0.54 or &lt; 0.075 proportion of red blood cells (RBC) in blood for hematocrit, &lt;25 or &gt;180 g/L for hemoglobin, 0.8 x10^9 cells/L for lymphocytes, &lt;1.5 x10^9 cells/L for neutrophils, &lt;100 or &gt;550 x10^9 cells/L for platelets and &lt;3 or 20&gt; x 10^9 cells per liter WBC. Participants were counted in the worst case category that their value changed to low, normal or high. If values were unchanged (example: High to High), or whose value became normal, were recorded in 'No Change' category.</description>
          <population>Safety population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Worst Case Hematology Parameters by Potential Clinical Importance Criteria: Part B</title>
        <description>Blood samples were collected from participants for analysis of following hematology parameters; hematocrit, hemoglobin, lymphocytes, platelet count, total neutrophils and WBC counts. PCI ranges were &gt;0.54 or &lt; 0.075 proportion of RBC in blood for hematocrit, &lt;25 or &gt;180 g/L for hemoglobin, 0.8 x10^9 cells/L for lymphocytes, &lt;1.5 x10^9 cells/L for neutrophils, &lt;100 or &gt;550 x10^9 cells/L for platelets and &lt;3 or 20&gt; x 10^9 cells per liter WBC. Participants were counted in the worst case category that their value changed to low, normal or high. If values were unchanged (example: High to High), or whose value became normal, were recorded in 'No Change' category.</description>
        <time_frame>Up to Week 4</time_frame>
        <population>Safety population. GSK2982772 360 mg BID of Part B was not started as one participant in GSK2982772 360 mg BID of Part A exceeded the Cmax stopping criteria</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:Placebo</title>
            <description>Participants received matching oral placebo capsule to GSK2928772 for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B:GSK2982772 360 mg BID</title>
            <description>Participants were planned to receive GSK2982772 oral capsule at a dose of 360 mg BID for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Worst Case Hematology Parameters by Potential Clinical Importance Criteria: Part B</title>
          <description>Blood samples were collected from participants for analysis of following hematology parameters; hematocrit, hemoglobin, lymphocytes, platelet count, total neutrophils and WBC counts. PCI ranges were &gt;0.54 or &lt; 0.075 proportion of RBC in blood for hematocrit, &lt;25 or &gt;180 g/L for hemoglobin, 0.8 x10^9 cells/L for lymphocytes, &lt;1.5 x10^9 cells/L for neutrophils, &lt;100 or &gt;550 x10^9 cells/L for platelets and &lt;3 or 20&gt; x 10^9 cells per liter WBC. Participants were counted in the worst case category that their value changed to low, normal or high. If values were unchanged (example: High to High), or whose value became normal, were recorded in 'No Change' category.</description>
          <population>Safety population. GSK2982772 360 mg BID of Part B was not started as one participant in GSK2982772 360 mg BID of Part A exceeded the Cmax stopping criteria</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Worst Case Urinalysis Results: Part A</title>
        <description>Urine samples were collected from participants for analysis of following parameters: cellular casts, granular casts, hyaline casts, RBC and WBC and were counted as cells per high-power field (cells/HPF). The number of participants with cells in urine has been presented.</description>
        <time_frame>Up to Week 9</time_frame>
        <population>Safety population. Only those participants with available data at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:Placebo</title>
            <description>Participants received matching oral placebo capsule to GSK2928772</description>
          </group>
          <group group_id="O2">
            <title>Part A:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID</description>
          </group>
          <group group_id="O3">
            <title>Part A:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID</description>
          </group>
          <group group_id="O4">
            <title>Part A:GSK2982772 360 mg BID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 360 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Worst Case Urinalysis Results: Part A</title>
          <description>Urine samples were collected from participants for analysis of following parameters: cellular casts, granular casts, hyaline casts, RBC and WBC and were counted as cells per high-power field (cells/HPF). The number of participants with cells in urine has been presented.</description>
          <population>Safety population. Only those participants with available data at specified time points were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cellular casts, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cellular casts, Any increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cellular casts, Increase to 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cellular casts, Increase to 10-50/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granular casts, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granular casts, Any increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granular casts, Increase 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granular casts, Increase 10-50/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyaline casts, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyaline casts, Any increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyaline casts, Increase 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyaline casts, Increase 10-50/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Any increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Increase 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Increase 10-50/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Any increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Increase 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Increase 10-50/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Worst Case Urinalysis Results: Part B</title>
        <description>Urine samples were collected from participants for analysis of following parameters: cellular casts, granular casts, hyaline casts, RBC and WBC and were counted as cells per high-power field (cells/HPF). The number of participants with cells in urine has been presented.</description>
        <time_frame>Up to Week 4</time_frame>
        <population>Safety population. GSK2982772 360 mg BID of Part B was not started as one participant in GSK2982772 360 mg BID of Part A exceeded the Cmax stopping criteria. Only those participants with data available at specified timepoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:Placebo</title>
            <description>Participants received matching oral placebo capsule to GSK2928772 for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B:GSK2982772 360 mg BID</title>
            <description>Participants were planned to receive GSK2982772 oral capsule at a dose of 360 mg BID for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Worst Case Urinalysis Results: Part B</title>
          <description>Urine samples were collected from participants for analysis of following parameters: cellular casts, granular casts, hyaline casts, RBC and WBC and were counted as cells per high-power field (cells/HPF). The number of participants with cells in urine has been presented.</description>
          <population>Safety population. GSK2982772 360 mg BID of Part B was not started as one participant in GSK2982772 360 mg BID of Part A exceeded the Cmax stopping criteria. Only those participants with data available at specified timepoints were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cellular casts, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cellular casts, Any increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cellular casts, Increase to 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cellular casts, Increase to 10-50/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granular casts, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granular casts, Any increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granular casts, Increase 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granular casts, Increase 10-50/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyaline casts, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyaline casts, Any increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyaline casts, Increase 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyaline casts, Increase 10-50/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Any increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Increase 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, Increase 10-50/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Any increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Increase 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Increase 10-50/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Vital Signs: Part A</title>
        <description>Vital signs were measured in a supine position after 5 minutes rest. The PCI criteria for vital signs included: systolic blood pressure &lt;85 and &gt;160 millimeters of mercury [mmHg]), diastolic blood pressure &lt;45 mmHg and &gt;100 mmHg, heart rate &lt;40 and &gt;100 beats per minute, body temperature &lt;=35.5 and &gt;=37.8 degrees Celsius and respiration rate &lt;=8 and &gt;=20 breaths per minute. Data of participants with potential clinical importance has been reported.</description>
        <time_frame>Up to Week 9</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:Placebo</title>
            <description>Participants received matching oral placebo capsule to GSK2928772</description>
          </group>
          <group group_id="O2">
            <title>Part A:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID</description>
          </group>
          <group group_id="O3">
            <title>Part A:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID</description>
          </group>
          <group group_id="O4">
            <title>Part A:GSK2982772 360 mg BID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 360 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Vital Signs: Part A</title>
          <description>Vital signs were measured in a supine position after 5 minutes rest. The PCI criteria for vital signs included: systolic blood pressure &lt;85 and &gt;160 millimeters of mercury [mmHg]), diastolic blood pressure &lt;45 mmHg and &gt;100 mmHg, heart rate &lt;40 and &gt;100 beats per minute, body temperature &lt;=35.5 and &gt;=37.8 degrees Celsius and respiration rate &lt;=8 and &gt;=20 breaths per minute. Data of participants with potential clinical importance has been reported.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Vital Signs: Part B</title>
        <description>Vital signs were measured in a supine position after 5 minutes rest. The PCI criteria for vital signs included: systolic blood pressure &lt;85 and &gt;160 mmHg, diastolic blood pressure &lt;45 mmHg and &gt;100 mmHg, heart rate &lt;40 and &gt;100 beats per minute, body temperature &lt;=35.5 and &gt;=37.8 degrees Celsius and respiration rate &lt;=8 and &gt;=20 breaths per minute. Data of participants with potential clinical importance has been reported.</description>
        <time_frame>Up to Week 4</time_frame>
        <population>Safety population. GSK2982772 360 mg BID of Part B was not started as one participant in GSK2982772 360 mg BID of Part A exceeded the Cmax stopping criteria</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:Placebo</title>
            <description>Participants received matching oral placebo capsule to GSK2928772 for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B:GSK2982772 360 mg BID</title>
            <description>Participants were planned to receive GSK2982772 oral capsule at a dose of 360 mg BID for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Vital Signs: Part B</title>
          <description>Vital signs were measured in a supine position after 5 minutes rest. The PCI criteria for vital signs included: systolic blood pressure &lt;85 and &gt;160 mmHg, diastolic blood pressure &lt;45 mmHg and &gt;100 mmHg, heart rate &lt;40 and &gt;100 beats per minute, body temperature &lt;=35.5 and &gt;=37.8 degrees Celsius and respiration rate &lt;=8 and &gt;=20 breaths per minute. Data of participants with potential clinical importance has been reported.</description>
          <population>Safety population. GSK2982772 360 mg BID of Part B was not started as one participant in GSK2982772 360 mg BID of Part A exceeded the Cmax stopping criteria</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Electrocardiogram (ECG) Findings: Part A</title>
        <description>12-lead ECG's were obtained in the supine position after 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Clinically significant and not clinically significant abnormal ECG findings have been presented. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.</description>
        <time_frame>Up to Day 4</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:Placebo</title>
            <description>Participants received matching oral placebo capsule to GSK2928772</description>
          </group>
          <group group_id="O2">
            <title>Part A:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID</description>
          </group>
          <group group_id="O3">
            <title>Part A:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID</description>
          </group>
          <group group_id="O4">
            <title>Part A:GSK2982772 360 mg BID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 360 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Electrocardiogram (ECG) Findings: Part A</title>
          <description>12-lead ECG's were obtained in the supine position after 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Clinically significant and not clinically significant abnormal ECG findings have been presented. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal, not clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal, clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal ECG Findings: Part B</title>
        <description>12-lead ECG's were obtained in the supine position after 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Clinically significant and not clinically significant abnormal ECG findings have been presented. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.</description>
        <time_frame>Up to Week 4</time_frame>
        <population>Safety population. GSK2982772 360 mg BID of Part B was not started as one participant in GSK2982772 360 mg BID of Part A exceeded the Cmax stopping criteria</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:Placebo</title>
            <description>Participants received matching oral placebo capsule to GSK2928772 for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Part B:GSK2982772 360 mg BID</title>
            <description>Participants were planned to receive GSK2982772 oral capsule at a dose of 360 mg BID for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal ECG Findings: Part B</title>
          <description>12-lead ECG's were obtained in the supine position after 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Clinically significant and not clinically significant abnormal ECG findings have been presented. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.</description>
          <population>Safety population. GSK2982772 360 mg BID of Part B was not started as one participant in GSK2982772 360 mg BID of Part A exceeded the Cmax stopping criteria</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal, not clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal, clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours (AUC[0-24]) Following TID Dosing of GSK2982772: Part A</title>
        <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 20, 40minutes, 1 hour, 1hr 30min, 2, 3, 5, 7hour, 7hr 20min,and 7hr 40 min, 8hr, 8hr 30min, 9hr, 10hr, 12hr, 14hr, 14hr 20min, 14hr 40 min, 15hr, 15hr 30min, 16hr, 17hr, 19hr, 22hr, 24hours post dose on Day1</time_frame>
        <population>Pharmacokinetic population. Pharmacokinetic population consists of participants in the safety population for whom a pharmacokinetic sample were obtained and analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID</description>
          </group>
          <group group_id="O2">
            <title>Part A:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours (AUC[0-24]) Following TID Dosing of GSK2982772: Part A</title>
          <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population. Pharmacokinetic population consists of participants in the safety population for whom a pharmacokinetic sample were obtained and analyzed.</population>
          <units>Hours*microgram per millilter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.22" spread="41.37"/>
                    <measurement group_id="O2" value="46.13" spread="37.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-24) Following BID Dosing of GSK2982772: Part A</title>
        <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 20min, 40min, 1hr, 1hr 30min, 2hr, 3hr, 4hr, 6hr, 8hr, 10hr, 12hr, 12hr 20min, 12hr 40min, 13hr, 13hr 30min, 14hr, 15hr, 16hr, 19hr, 22hr, 24hr post dose on Day 1.</time_frame>
        <population>Pharmacokinetic population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 360 mg BID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 360 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24) Following BID Dosing of GSK2982772: Part A</title>
          <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population.</population>
          <units>Hours*microgram per millilter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.02" spread="36.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC[0-24] Following TID Dosing of GSK2982772: Part B</title>
        <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 20, 40minutes, 1 hour, 1hr 30min, 2, 3, 5, 7hour, 7hr 20min,and 7hr 40 min, 8hr, 8hr 30min, 9hr, 10hr, 12hr, 14hr, 14hr 20min, 14hr 40 min, 15hr, 15hr 30min, 16hr, 17hr, 19hr, 22hr, 24hours post dose on Day14</time_frame>
        <population>Pharmacokinetic population. Only those participants with data available at the specified timepoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC[0-24] Following TID Dosing of GSK2982772: Part B</title>
          <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population. Only those participants with data available at the specified timepoints were analyzed.</population>
          <units>Hours*microgram per millilter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.67" spread="28.81"/>
                    <measurement group_id="O2" value="52.00" spread="45.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (0-7) Following TID Dosing of GSK2982772 : Part A</title>
        <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, 7 hours on Day 1</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID</description>
          </group>
          <group group_id="O2">
            <title>Part A:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-7) Following TID Dosing of GSK2982772 : Part A</title>
          <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population</population>
          <units>Hours*microgram per millilter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.053" spread="33.87"/>
                    <measurement group_id="O2" value="11.686" spread="33.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (7-14) Following TID Dosing of GSK2982772 : Part A</title>
        <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>7 hours, 7 hours 20 and 40 minutes, 8 hours, 8 hours 30 minutes, 9, 10, 12, 14 hours on Day 1</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID</description>
          </group>
          <group group_id="O2">
            <title>Part A:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (7-14) Following TID Dosing of GSK2982772 : Part A</title>
          <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population</population>
          <units>Hours*microgram per millilter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.829" spread="44.25"/>
                    <measurement group_id="O2" value="17.823" spread="42.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (14-24) Following TID Dosing of GSK2982772 : Part A</title>
        <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>14 hours, 14 hours 20 and 40 minutes, 15 hours ,15 hours 30 minutes, 16, 19, 22 and 24 hours on Day 1</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID</description>
          </group>
          <group group_id="O2">
            <title>Part A:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (14-24) Following TID Dosing of GSK2982772 : Part A</title>
          <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population</population>
          <units>Hours*microgram per millilter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.213" spread="48.85"/>
                    <measurement group_id="O2" value="16.300" spread="39.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (0-12) Following BID Dosing of GSK2982772 in Part A</title>
        <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 4, 6, 8, 10 hours,12 hours on Day 1</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 360 mg BID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 360 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-12) Following BID Dosing of GSK2982772 in Part A</title>
          <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population</population>
          <units>Hours*microgram per millilter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.80" spread="24.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (12-24) Following BID Dosing of GSK2982772 in Part A</title>
        <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>12 hours, 12 hours 20 and 40 minutes, 13 and 13 hours 30 minutes, 14, 15, 16, 19, 22 and 24 hours on Day 1</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 360 mg BID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 360 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (12-24) Following BID Dosing of GSK2982772 in Part A</title>
          <description>Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population</population>
          <units>Hours*microgram per millilter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.69" spread="48.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-7) Following TID Dosing of GSK2982772 in Part B</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, 7 hours on Days 1 and 14</time_frame>
        <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-7) Following TID Dosing of GSK2982772 in Part B</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
          <units>Hour*microgram per millilter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0-7), Day 1, n=20, 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.550" spread="37.67"/>
                    <measurement group_id="O2" value="11.895" spread="33.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-7), Day 14, n=10, 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.485" spread="25.53"/>
                    <measurement group_id="O2" value="14.835" spread="45.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (7-14) Following TID Dosing of GSK2982772 in Part B</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>7 and 7 hours 20 and 40 minutes, 8 and 8 hours 30 minutes, 9, 10, 12, 14 hours on Day 14</time_frame>
        <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (7-14) Following TID Dosing of GSK2982772 in Part B</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Hours*microgram per millilter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.095" spread="30.57"/>
                    <measurement group_id="O2" value="17.372" spread="34.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (14-24) Following TID Dosing of GSK2982772 in Part B</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>14 hours, 14 hours 20 minutes, 14 hours 40 minutes, 15 hours, 15 hours 30 minutes, 16, 17, 19, 22 and 24 hours on Day 14</time_frame>
        <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (14-24) Following TID Dosing of GSK2982772 in Part B</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed</population>
          <units>Hours*microgram per millilter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.988" spread="33.57"/>
                    <measurement group_id="O2" value="19.816" spread="55.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Drug Concentration Cmax (0-7) Following TID Dosing of GSK2982772 in Part A</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, and 7 hours post dose on Day 1</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID</description>
          </group>
          <group group_id="O2">
            <title>Part A:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Drug Concentration Cmax (0-7) Following TID Dosing of GSK2982772 in Part A</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7672" spread="41.78"/>
                    <measurement group_id="O2" value="3.3125" spread="25.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (7-14) Following TID Dosing of GSK2982772 in Part A</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>7 hours, 7 hours 20 and 40 minutes, 8 and 8 hours 30 minutes, 9, 10, 12, 14 hours post dose on Day 1</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID</description>
          </group>
          <group group_id="O2">
            <title>Part A:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (7-14) Following TID Dosing of GSK2982772 in Part A</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.148" spread="36.24"/>
                    <measurement group_id="O2" value="5.007" spread="33.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (14-24) Following TID Dosing of GSK2982772 in Part A</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>14 hours, 14 hours 20 and 40 minutes, 15 and 15 hours 30 minutes, 16, 19, 22 and 24 hours post dose on Day 1</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID</description>
          </group>
          <group group_id="O2">
            <title>Part A:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (14-24) Following TID Dosing of GSK2982772 in Part A</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4156" spread="47.03"/>
                    <measurement group_id="O2" value="3.4812" spread="28.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (0-12) Following BID Dosing of GSK2982772 in Part A</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 4, 6, 8, 10 hours and 12 hours post dose on Day 1</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 360 mg BID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 360 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (0-12) Following BID Dosing of GSK2982772 in Part A</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.967" spread="30.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (12-24) Following BID Dosing of GSK2982772 in Part A</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>12 hours, 12 hours 20 and 40 minutes, 13 and 13 hours 30 minutes, 14, 15, 16, 19, 22 and 24 hours post dose on Day 1</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 360 mg BID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 360 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (12-24) Following BID Dosing of GSK2982772 in Part A</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.965" spread="61.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (0-7) Following TID Dosing of GSK2982772 in Part B</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, 7 hours post dose on Days 1 and 14</time_frame>
        <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (0-7) Following TID Dosing of GSK2982772 in Part B</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax (0-7), Day 1, n=20, 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0883" spread="37.87"/>
                    <measurement group_id="O2" value="3.2333" spread="37.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax (0-7), Day 14, n=10, 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2239" spread="30.03"/>
                    <measurement group_id="O2" value="4.3784" spread="45.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (7-14) Following TID Dosing of GSK2982772 in Part B</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>7hours, 7 hours 20 and 40 minutes, 8 hours, 8 hours 30 minutes, 9, 10, 12, 14 hours on Day 14</time_frame>
        <population>Pharmacokinetic population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (7-14) Following TID Dosing of GSK2982772 in Part B</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.505" spread="26.70"/>
                    <measurement group_id="O2" value="5.435" spread="32.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (14-24) Following TID Dosing of GSK2982772 in Part B</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>14 hours, 14 hours 20 and 40 minutes, 15 hours, 15 hours 30 minutes, 16, 17, 19, 22 and 24 hours post dose on Day 14</time_frame>
        <population>Pharmacokinetic population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (14-24) Following TID Dosing of GSK2982772 in Part B</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population.</population>
          <units>Microgram per millilter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9205" spread="30.82"/>
                    <measurement group_id="O2" value="4.1607" spread="38.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cmax (Tmax) (0-7) Following TID Dosing of GSK2982772 in Part A</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, and 7 hours post dose on Day 1</time_frame>
        <population>Pharmacokinetic population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID</description>
          </group>
          <group group_id="O2">
            <title>Part A:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cmax (Tmax) (0-7) Following TID Dosing of GSK2982772 in Part A</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.008" lower_limit="2.00" upper_limit="5.02"/>
                    <measurement group_id="O2" value="2.043" lower_limit="1.50" upper_limit="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax (7-14) Following TID Dosing of GSK2982772 in Part A</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>7hours, 7 hours 20 and 40 minutes, 8 hours, 8 hours 30 minutes, 9, 10, 12, 14 hours post dose on Day 1</time_frame>
        <population>Pharmacokinetic population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID</description>
          </group>
          <group group_id="O2">
            <title>Part A:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (7-14) Following TID Dosing of GSK2982772 in Part A</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.000" lower_limit="8.00" upper_limit="12.00"/>
                    <measurement group_id="O2" value="9.000" lower_limit="8.50" upper_limit="10.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax (14-24) Following TID Dosing of GSK2982772 in Part A</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>14 hours, 14 hours 20 and 40 minutes, 15 hours, 15 hours 30 minutes, 16, 17, 19, 22 and 24 hours post dose on Day 1</time_frame>
        <population>Pharmacokinetic population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID</description>
          </group>
          <group group_id="O2">
            <title>Part A:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (14-24) Following TID Dosing of GSK2982772 in Part A</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.00" lower_limit="16.0" upper_limit="22.0"/>
                    <measurement group_id="O2" value="17.02" lower_limit="16.0" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax (0-12) Following BID Dosing of GSK2982772 in Part A</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 20 and 40 minutes, 1hour, 1 hour 30 minutes, 2, 3, 4, 6, 8, 10 hours and 12 hours post dose on Day 1</time_frame>
        <population>Pharmacokinetic population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 360 mg BID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 360 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (0-12) Following BID Dosing of GSK2982772 in Part A</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.000" lower_limit="1.50" upper_limit="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax (12-24) Following BID Dosing of GSK2982772 in Part A</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>12 hours, 12 hours 20 and 40 minutes, 13 hours, 13 hours 30 minutes, 14, 15, 16, 19, 22 and 24 hours post dose on Day 1</time_frame>
        <population>Pharmacokinetic population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 360 mg BID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 360 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (12-24) Following BID Dosing of GSK2982772 in Part A</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.01" lower_limit="13.5" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax (0-7) Following TID Dosing of GSK2982772 Part B</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 20 and 40 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 5, 7 hours post dose on Days 1 and 14</time_frame>
        <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (0-7) Following TID Dosing of GSK2982772 Part B</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax (0-7), Day 1, n=20, 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.000" lower_limit="1.00" upper_limit="3.01"/>
                    <measurement group_id="O2" value="3.000" lower_limit="1.00" upper_limit="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax (0-7), Day 14, n=10, 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.750" lower_limit="1.00" upper_limit="3.03"/>
                    <measurement group_id="O2" value="2.003" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax (7-14) Following TID Dosing of GSK2982772 in Part B</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>7hours and 7 hours 20 and 40 minutes, 8hours, 8 hours 30 minutes, 9, 10, 12, 14 hours post dose on Day 14</time_frame>
        <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (7-14) Following TID Dosing of GSK2982772 in Part B</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.001" lower_limit="8.50" upper_limit="10.00"/>
                    <measurement group_id="O2" value="10.008" lower_limit="8.50" upper_limit="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax (14-24) Following TID Dosing of GSK2982772 in Part B</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>14hours, 14 hours 20 and 40 minutes, 15 hours and 15 hours 30 minutes, 16, 17, 19, 22 and 24 hours post dose on Day 14</time_frame>
        <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (14-24) Following TID Dosing of GSK2982772 in Part B</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.02" lower_limit="15.0" upper_limit="19.0"/>
                    <measurement group_id="O2" value="18.92" lower_limit="16.0" upper_limit="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Trough Plasma Drug Concentration at 7 Hour (C7),Following TID Dosing of GSK2982772 in Part A</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>7 hours post-dose on Day 1</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID</description>
          </group>
          <group group_id="O2">
            <title>Part A:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Trough Plasma Drug Concentration at 7 Hour (C7),Following TID Dosing of GSK2982772 in Part A</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3614" spread="84.67"/>
                    <measurement group_id="O2" value="0.7723" spread="89.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Trough Plasma Drug Concentration at 14 Hours (C14) Following TID Dosing of GSK2982772 in Part A</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>14 hours post-dose on Day 1</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID</description>
          </group>
          <group group_id="O2">
            <title>Part A:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Trough Plasma Drug Concentration at 14 Hours (C14) Following TID Dosing of GSK2982772 in Part A</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4318" spread="86.28"/>
                    <measurement group_id="O2" value="0.7487" spread="76.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C24 Following TID Dosing of GSK2982772 in Part A</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>24 hours post-dose on Day 1</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID</description>
          </group>
          <group group_id="O2">
            <title>Part A:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID</description>
          </group>
        </group_list>
        <measure>
          <title>C24 Following TID Dosing of GSK2982772 in Part A</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34518" spread="82.34"/>
                    <measurement group_id="O2" value="0.59880" spread="158.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C12 Following BID Dosing of GSK2982772 in Part A</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.&#xD;
Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>12 hours post-dose on Day 1</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 360 mg BID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 360 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>C12 Following BID Dosing of GSK2982772 in Part A</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.&#xD;
Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population</population>
          <units>Microgram per millilter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3490" spread="98.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C24 Following BID Dosing of GSK2982772 in Part A</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>24 hours post-dose on Day 1</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:GSK2982772 360 mg BID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 360 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>C24 Following BID Dosing of GSK2982772 in Part A</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population</population>
          <units>Microgram per millililter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36965" spread="101.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C0 Following TID Dosing of GSK2982772 in Part B</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose on Day 14</time_frame>
        <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>C0 Following TID Dosing of GSK2982772 in Part B</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29926" spread="56.63"/>
                    <measurement group_id="O2" value="0.57528" spread="136.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C7 Following TID Dosing of GSK2982772 in Part B</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>7 hours post-dose on Days 1 and 14</time_frame>
        <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>C7 Following TID Dosing of GSK2982772 in Part B</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C7, Day 1, n=20, 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3345" spread="50.78"/>
                    <measurement group_id="O2" value="0.6105" spread="57.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C7, Day 14, n=10, 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3718" spread="43.85"/>
                    <measurement group_id="O2" value="0.6885" spread="75.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C14 Following TID Dosing of GSK2982772 in Part B</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>14 hours post-dose on Day 14</time_frame>
        <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>C14 Following TID Dosing of GSK2982772 in Part B</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3830" spread="53.04"/>
                    <measurement group_id="O2" value="0.6912" spread="106.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C24 Following TID Dosing of GSK2982772 in Part B</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>24 hours post-dose on Day 14</time_frame>
        <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>C24 Following TID Dosing of GSK2982772 in Part B</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22712" spread="60.78"/>
                    <measurement group_id="O2" value="0.33342" spread="180.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC([0-7] Following TID Dosing of GSK2982772 in Fed State of Part B</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, 7 hours on Days 9 and 11</time_frame>
        <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC([0-7] Following TID Dosing of GSK2982772 in Fed State of Part B</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Hours*micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0-7) following normal breakfast, Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.743" spread="31.46"/>
                    <measurement group_id="O2" value="14.691" spread="37.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-7) following high fat breakfast, Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.874" spread="24.64"/>
                    <measurement group_id="O2" value="15.987" spread="42.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (0-7) Following TID Dosing of GSK2982772 in Fed State of Part B</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, 7 hours on Days 9 and 11</time_frame>
        <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (0-7) Following TID Dosing of GSK2982772 in Fed State of Part B</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax(0-7), following Normal Breakfast, Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0918" spread="21.74"/>
                    <measurement group_id="O2" value="3.9440" spread="33.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax(0-7), following High Fat Breakfast, Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8098" spread="29.77"/>
                    <measurement group_id="O2" value="4.1171" spread="58.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax (0-7) Following TID Dosing of GSK2982772 in Fed State of Part B</title>
        <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, 7 hours on Days 9 and 11</time_frame>
        <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (0-7) Following TID Dosing of GSK2982772 in Fed State of Part B</title>
          <description>Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax(0-7), Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.000" lower_limit="1.04" upper_limit="5.00"/>
                    <measurement group_id="O2" value="3.000" lower_limit="2.00" upper_limit="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax (0-7), Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.000" lower_limit="1.50" upper_limit="5.00"/>
                    <measurement group_id="O2" value="3.000" lower_limit="2.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Plasma 4 Beta-hydroxycholesterol to Cholesterol: Part B</title>
        <description>Blood samples were collected into EDTA tubes and processed to plasma for 4 beta-hydroxycholesterol and cholesterol. Ratio of 4 beta-hydroxycholesterol to cholesterol is presented</description>
        <time_frame>Pre-dose on Day 1 and 24 hours post first dose on Day 14</time_frame>
        <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B:Placebo</title>
            <description>Participants received matching oral placebo capsule to GSK2928772 for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Part B:GSK2982772 120 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Part B:GSK2982772 240 mg TID</title>
            <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Plasma 4 Beta-hydroxycholesterol to Cholesterol: Part B</title>
          <description>Blood samples were collected into EDTA tubes and processed to plasma for 4 beta-hydroxycholesterol and cholesterol. Ratio of 4 beta-hydroxycholesterol to cholesterol is presented</description>
          <population>Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, Pre-dose; n=0, 19, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.000019" spread="0.0000064"/>
                    <measurement group_id="O3" value="0.000023" spread="0.0000099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 24 hour; n=1, 10, 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000016" spread="NA">Not applicable (NA) indicates that standard deviation could not be calculated for a single participant.</measurement>
                    <measurement group_id="O2" value="0.000021" spread="0.0000089"/>
                    <measurement group_id="O3" value="0.000024" spread="0.0000065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On-treatment SAEs and non serious AEs were collected from the start of study treatment up to Day 14 for Part A and up to Day 28 for Part B.</time_frame>
      <desc>Safety population consists of all randomized participants who take at least 1 dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part A: Placebo</title>
          <description>Participants received matching oral placebo capsule to GSK2928772</description>
        </group>
        <group group_id="E2">
          <title>Part A:GSK2982772 120 mg TID</title>
          <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID</description>
        </group>
        <group group_id="E3">
          <title>Part A: GSK2982772 240 mg TID</title>
          <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID</description>
        </group>
        <group group_id="E4">
          <title>Part A: GSK2982772 360 mg BID</title>
          <description>Participants received GSK2982772 oral capsule at a dose of 360 mg BID</description>
        </group>
        <group group_id="E5">
          <title>Part B:Placebo</title>
          <description>Participants received matching oral placebo capsule to GSK2928772 for 14 days.</description>
        </group>
        <group group_id="E6">
          <title>Part B: GSK2982772 120 mg TID</title>
          <description>Participants received GSK2982772 oral capsule at a dose of 120 mg TID for 14 days</description>
        </group>
        <group group_id="E7">
          <title>Part B: GSK2982772 240 mg TID</title>
          <description>Participants received GSK2982772 oral capsule at a dose of 240 mg TID for 14 days</description>
        </group>
        <group group_id="E8">
          <title>Part B: GSK2982772 360 mg BID</title>
          <description>Participants were planned to receive GSK2982772 oral capsule at a dose of 360 mg TID for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Faeces soft</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Medical device site dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Catheter site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Catheter site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Antinuclear antibody positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03305419
org study id: 205184
secondary id: 2017-002662-45
nct id: NCT03305419
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
This study is designed to evaluate the safety, tolerability and PK of GSK2982772, in repeat
      oral doses in healthy subjects. This study is being conducted to support administration of
      higher dose levels of GSK2982772 than initially studied in the First Time in Human (FTiH)
      study. This study will also assess the impact of food during the repeat doses of GSK2982772.
      This will be a two part study; Part A and Part B. Part A (cohort 1) - single ascending dose,
      randomized, placebo-controlled, 3-way crossover. Part B (cohorts 2, 3, 4 and 5) - repeat
      dose, randomized, placebo-controlled, sequential-group. Subjects will be randomized in 3:1
      ratio to receive GSK2982772 or placebo in crossover manner on Day 1 of each of the three
      periods in Part A. Subjects will be randomized in 3:1 ratio to receive GSK2982772 or placebo
      in sequential groups for 14 days in cohort 2 of Part B and in 9:5 ratio to receive GSK2982772
      or placebo in sequential groups for 14 days in cohorts 3, 4 and 5 of Part B. Approximately 66
      subjects will be included in this study. The study duration, including screening and
      follow-up, will not be expected to exceed 13 weeks for Part A and 8 weeks for Part B.
allocation: Randomized
intervention model: Sequential Assignment
intervention model description: This study will consist of two parts; Part A and Part B. Part A will be a 3-way crossover design and Part B will be a sequential-group design.
primary purpose: Treatment
masking: Double (Participant, Investigator)
masking description: This will be a double-blind study. Subjects and investigator will be masked.
measure: Number of Subjects With Adverse Events (AEs) and Serious AEs (SAEs): Part A
time frame: Up to Day 14
description: An AE is any untoward medical occurrence in a clinical study subjects, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment will be categorized as SAE.
measure: Number of Participants With AEs and SAEs: Part B
time frame: Up to Day 28
description: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment were categorized as SAE.
measure: Number of Participants With Worst Case Clinical Chemistry Parameters by Potential Clinical Importance Criteria: Part A
time frame: Up to Week 9
description: Blood samples were collected from participants for the analysis of following clinical chemistry parameters: alanine amino transferase (ALT), albumin, alkaline phosphatase, aspartate amino transferase (AST), calcium, creatinine, glucose, potassium, sodium and total bilirubin. PCI ranges were >=2 times Upper Limit of Normal (ULN) units per liter (U/L) for ALT, <30 grams per liter (g/L) for albumin, >=2 times ULN U/L for alkaline phosphatase, >=2 times ULN U/L for AST, <2 or >2.75 millimoles per liter (mmol/L) for calcium, >44.2 micromoles per liter (µmol/L) for creatinine, <3 or >9 mmol/L for glucose, <3 or >5.5 mmol/L for potassium, <130 or >150 mmol/L for sodium and >=1.5 times ULN for total bilirubin. Participants were counted in the worst case category that their value changed to low, normal or high. If values were unchanged (example: High to High), or whose value became normal, were recorded in 'No Change' category.
measure: Number of Participants With Worst Case Clinical Chemistry Parameters by Potential Clinical Importance Criteria: Part B
time frame: Up to Week 4
description: Blood samples were collected from participants for the analysis of following clinical chemistry parameters: ALT, albumin, alkaline phosphatase, AST, calcium, creatinine, glucose, potassium, sodium and total bilirubin. PCI ranges were >=2 times ULN U/L for ALT, <30 g/L for albumin, >=2 times ULN U/L for alkaline phosphatase, >=2 times ULN U/L for AST, <2 or >2.75 mmol/L for calcium, >44.2 µmol/L for creatinine, <3 or >9 mmol/L for glucose, <3 or >5.5 mmol/L for potassium, <130 or >150 mmol/L for sodium and >=1.5 times ULN for total bilirubin. Participants were counted in the worst case category that their value changed to low, normal or high. If values were unchanged (example: High to High), or whose value became normal, were recorded in 'No Change' category.
measure: Number of Participants With Worst Case Hematology Parameters by Potential Clinical Importance Criteria: Part A
time frame: Up to Week 9
description: Blood samples were collected from participants for analysis of following hematology parameters; hematocrit, hemoglobin, lymphocytes, platelet count, total neutrophils and white blood cell (WBC) counts. PCI ranges were >0.54 or < 0.075 proportion of red blood cells (RBC) in blood for hematocrit, <25 or >180 g/L for hemoglobin, 0.8 x10^9 cells/L for lymphocytes, <1.5 x10^9 cells/L for neutrophils, <100 or >550 x10^9 cells/L for platelets and <3 or 20> x 10^9 cells per liter WBC. Participants were counted in the worst case category that their value changed to low, normal or high. If values were unchanged (example: High to High), or whose value became normal, were recorded in 'No Change' category.
measure: Number of Participants With Worst Case Hematology Parameters by Potential Clinical Importance Criteria: Part B
time frame: Up to Week 4
description: Blood samples were collected from participants for analysis of following hematology parameters; hematocrit, hemoglobin, lymphocytes, platelet count, total neutrophils and WBC counts. PCI ranges were >0.54 or < 0.075 proportion of RBC in blood for hematocrit, <25 or >180 g/L for hemoglobin, 0.8 x10^9 cells/L for lymphocytes, <1.5 x10^9 cells/L for neutrophils, <100 or >550 x10^9 cells/L for platelets and <3 or 20> x 10^9 cells per liter WBC. Participants were counted in the worst case category that their value changed to low, normal or high. If values were unchanged (example: High to High), or whose value became normal, were recorded in 'No Change' category.
measure: Number of Participants With Worst Case Urinalysis Results: Part A
time frame: Up to Week 9
description: Urine samples were collected from participants for analysis of following parameters: cellular casts, granular casts, hyaline casts, RBC and WBC and were counted as cells per high-power field (cells/HPF). The number of participants with cells in urine has been presented.
measure: Number of Participants With Worst Case Urinalysis Results: Part B
time frame: Up to Week 4
description: Urine samples were collected from participants for analysis of following parameters: cellular casts, granular casts, hyaline casts, RBC and WBC and were counted as cells per high-power field (cells/HPF). The number of participants with cells in urine has been presented.
measure: Number of Participants With Abnormal Vital Signs: Part A
time frame: Up to Week 9
description: Vital signs were measured in a supine position after 5 minutes rest. The PCI criteria for vital signs included: systolic blood pressure <85 and >160 millimeters of mercury [mmHg]), diastolic blood pressure <45 mmHg and >100 mmHg, heart rate <40 and >100 beats per minute, body temperature <=35.5 and >=37.8 degrees Celsius and respiration rate <=8 and >=20 breaths per minute. Data of participants with potential clinical importance has been reported.
measure: Number of Participants With Abnormal Vital Signs: Part B
time frame: Up to Week 4
description: Vital signs were measured in a supine position after 5 minutes rest. The PCI criteria for vital signs included: systolic blood pressure <85 and >160 mmHg, diastolic blood pressure <45 mmHg and >100 mmHg, heart rate <40 and >100 beats per minute, body temperature <=35.5 and >=37.8 degrees Celsius and respiration rate <=8 and >=20 breaths per minute. Data of participants with potential clinical importance has been reported.
measure: Number of Participants With Abnormal Electrocardiogram (ECG) Findings: Part A
time frame: Up to Day 4
description: 12-lead ECG's were obtained in the supine position after 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Clinically significant and not clinically significant abnormal ECG findings have been presented. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
measure: Number of Participants With Abnormal ECG Findings: Part B
time frame: Up to Week 4
description: 12-lead ECG's were obtained in the supine position after 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Clinically significant and not clinically significant abnormal ECG findings have been presented. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
measure: Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours (AUC[0-24]) Following TID Dosing of GSK2982772: Part A
time frame: Pre-dose, 20, 40minutes, 1 hour, 1hr 30min, 2, 3, 5, 7hour, 7hr 20min,and 7hr 40 min, 8hr, 8hr 30min, 9hr, 10hr, 12hr, 14hr, 14hr 20min, 14hr 40 min, 15hr, 15hr 30min, 16hr, 17hr, 19hr, 22hr, 24hours post dose on Day1
description: Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: AUC(0-24) Following BID Dosing of GSK2982772: Part A
time frame: Pre-dose, 20min, 40min, 1hr, 1hr 30min, 2hr, 3hr, 4hr, 6hr, 8hr, 10hr, 12hr, 12hr 20min, 12hr 40min, 13hr, 13hr 30min, 14hr, 15hr, 16hr, 19hr, 22hr, 24hr post dose on Day 1.
description: Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: AUC[0-24] Following TID Dosing of GSK2982772: Part B
time frame: Pre-dose, 20, 40minutes, 1 hour, 1hr 30min, 2, 3, 5, 7hour, 7hr 20min,and 7hr 40 min, 8hr, 8hr 30min, 9hr, 10hr, 12hr, 14hr, 14hr 20min, 14hr 40 min, 15hr, 15hr 30min, 16hr, 17hr, 19hr, 22hr, 24hours post dose on Day14
description: Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: AUC (0-7) Following TID Dosing of GSK2982772 : Part A
time frame: Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, 7 hours on Day 1
description: Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: AUC (7-14) Following TID Dosing of GSK2982772 : Part A
time frame: 7 hours, 7 hours 20 and 40 minutes, 8 hours, 8 hours 30 minutes, 9, 10, 12, 14 hours on Day 1
description: Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: AUC (14-24) Following TID Dosing of GSK2982772 : Part A
time frame: 14 hours, 14 hours 20 and 40 minutes, 15 hours ,15 hours 30 minutes, 16, 19, 22 and 24 hours on Day 1
description: Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: AUC (0-12) Following BID Dosing of GSK2982772 in Part A
time frame: Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 4, 6, 8, 10 hours,12 hours on Day 1
description: Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: AUC (12-24) Following BID Dosing of GSK2982772 in Part A
time frame: 12 hours, 12 hours 20 and 40 minutes, 13 and 13 hours 30 minutes, 14, 15, 16, 19, 22 and 24 hours on Day 1
description: Blood samples were collected at indicated timepoints for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: AUC(0-7) Following TID Dosing of GSK2982772 in Part B
time frame: Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, 7 hours on Days 1 and 14
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: AUC (7-14) Following TID Dosing of GSK2982772 in Part B
time frame: 7 and 7 hours 20 and 40 minutes, 8 and 8 hours 30 minutes, 9, 10, 12, 14 hours on Day 14
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: AUC (14-24) Following TID Dosing of GSK2982772 in Part B
time frame: 14 hours, 14 hours 20 minutes, 14 hours 40 minutes, 15 hours, 15 hours 30 minutes, 16, 17, 19, 22 and 24 hours on Day 14
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Maximum Observed Plasma Drug Concentration Cmax (0-7) Following TID Dosing of GSK2982772 in Part A
time frame: Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, and 7 hours post dose on Day 1
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Cmax (7-14) Following TID Dosing of GSK2982772 in Part A
time frame: 7 hours, 7 hours 20 and 40 minutes, 8 and 8 hours 30 minutes, 9, 10, 12, 14 hours post dose on Day 1
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Cmax (14-24) Following TID Dosing of GSK2982772 in Part A
time frame: 14 hours, 14 hours 20 and 40 minutes, 15 and 15 hours 30 minutes, 16, 19, 22 and 24 hours post dose on Day 1
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Cmax (0-12) Following BID Dosing of GSK2982772 in Part A
time frame: Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 4, 6, 8, 10 hours and 12 hours post dose on Day 1
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Cmax (12-24) Following BID Dosing of GSK2982772 in Part A
time frame: 12 hours, 12 hours 20 and 40 minutes, 13 and 13 hours 30 minutes, 14, 15, 16, 19, 22 and 24 hours post dose on Day 1
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Cmax (0-7) Following TID Dosing of GSK2982772 in Part B
time frame: Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, 7 hours post dose on Days 1 and 14
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Cmax (7-14) Following TID Dosing of GSK2982772 in Part B
time frame: 7hours, 7 hours 20 and 40 minutes, 8 hours, 8 hours 30 minutes, 9, 10, 12, 14 hours on Day 14
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Cmax (14-24) Following TID Dosing of GSK2982772 in Part B
time frame: 14 hours, 14 hours 20 and 40 minutes, 15 hours, 15 hours 30 minutes, 16, 17, 19, 22 and 24 hours post dose on Day 14
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Time to Cmax (Tmax) (0-7) Following TID Dosing of GSK2982772 in Part A
time frame: Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, and 7 hours post dose on Day 1
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Tmax (7-14) Following TID Dosing of GSK2982772 in Part A
time frame: 7hours, 7 hours 20 and 40 minutes, 8 hours, 8 hours 30 minutes, 9, 10, 12, 14 hours post dose on Day 1
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Tmax (14-24) Following TID Dosing of GSK2982772 in Part A
time frame: 14 hours, 14 hours 20 and 40 minutes, 15 hours, 15 hours 30 minutes, 16, 17, 19, 22 and 24 hours post dose on Day 1
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Tmax (0-12) Following BID Dosing of GSK2982772 in Part A
time frame: Pre-dose, 20 and 40 minutes, 1hour, 1 hour 30 minutes, 2, 3, 4, 6, 8, 10 hours and 12 hours post dose on Day 1
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Tmax (12-24) Following BID Dosing of GSK2982772 in Part A
time frame: 12 hours, 12 hours 20 and 40 minutes, 13 hours, 13 hours 30 minutes, 14, 15, 16, 19, 22 and 24 hours post dose on Day 1
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Tmax (0-7) Following TID Dosing of GSK2982772 Part B
time frame: Pre-dose, 20 and 40 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 5, 7 hours post dose on Days 1 and 14
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Tmax (7-14) Following TID Dosing of GSK2982772 in Part B
time frame: 7hours and 7 hours 20 and 40 minutes, 8hours, 8 hours 30 minutes, 9, 10, 12, 14 hours post dose on Day 14
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Tmax (14-24) Following TID Dosing of GSK2982772 in Part B
time frame: 14hours, 14 hours 20 and 40 minutes, 15 hours and 15 hours 30 minutes, 16, 17, 19, 22 and 24 hours post dose on Day 14
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Observed Trough Plasma Drug Concentration at 7 Hour (C7),Following TID Dosing of GSK2982772 in Part A
time frame: 7 hours post-dose on Day 1
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Observed Trough Plasma Drug Concentration at 14 Hours (C14) Following TID Dosing of GSK2982772 in Part A
time frame: 14 hours post-dose on Day 1
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: C24 Following TID Dosing of GSK2982772 in Part A
time frame: 24 hours post-dose on Day 1
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: C12 Following BID Dosing of GSK2982772 in Part A
time frame: 12 hours post-dose on Day 1
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: C24 Following BID Dosing of GSK2982772 in Part A
time frame: 24 hours post-dose on Day 1
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: C0 Following TID Dosing of GSK2982772 in Part B
time frame: Pre-dose on Day 14
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: C7 Following TID Dosing of GSK2982772 in Part B
time frame: 7 hours post-dose on Days 1 and 14
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: C14 Following TID Dosing of GSK2982772 in Part B
time frame: 14 hours post-dose on Day 14
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: C24 Following TID Dosing of GSK2982772 in Part B
time frame: 24 hours post-dose on Day 14
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: AUC([0-7] Following TID Dosing of GSK2982772 in Fed State of Part B
time frame: Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, 7 hours on Days 9 and 11
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Cmax (0-7) Following TID Dosing of GSK2982772 in Fed State of Part B
time frame: Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, 7 hours on Days 9 and 11
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Tmax (0-7) Following TID Dosing of GSK2982772 in Fed State of Part B
time frame: Pre-dose, 20 and 40 minutes, 1 and 1 hour 30 minutes, 2, 3, 5, 7 hours on Days 9 and 11
description: Blood samples were collected at indicated time-points for pharmacokinetic analysis of GSK2982772.Pharmacokinetic parameters were calculated by standard non-compartmental analysis.
measure: Ratio of Plasma 4 Beta-hydroxycholesterol to Cholesterol: Part B
time frame: Pre-dose on Day 1 and 24 hours post first dose on Day 14
description: Blood samples were collected into EDTA tubes and processed to plasma for 4 beta-hydroxycholesterol and cholesterol. Ratio of 4 beta-hydroxycholesterol to cholesterol is presented
arm group label: Subjects receiving treatment sequence ABC in cohort 1: Part A
arm group type: Experimental
description: Eligible subjects will be randomized to receive treatment sequence ABC in Part A; A= GSK2982772 120 mg TID, B= GSK2982772 240 mg TID, and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
arm group label: Subjects receiving treatment sequence ABP in cohort 1: Part A
arm group type: Experimental
description: Eligible subjects will be randomized to receive treatment sequence ABP in Part A; A= GSK2982772 120 mg TID, B= GSK2982772 240 mg TID, and P= Placebo. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
arm group label: Subjects receiving treatment sequence APC in cohort 1: Part A
arm group type: Experimental
description: Eligible subjects will be randomized to receive treatment sequence APC in Part A; A= GSK2982772 120 mg TID, P= Placebo and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
arm group label: Subjects receiving treatment sequence PBC in cohort 1: Part A
arm group type: Experimental
description: Eligible subjects will be randomized to receive treatment sequence PBC in Part A; P= Placebo, B= GSK2982772 240 mg TID and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
arm group label: Subjects receiving GSK2982772 120 mg TID in cohort 2 : Part B
arm group type: Experimental
description: Eligible subjects will receive GSK2982772 oral capsule with a dose of 120 mg TID for 14 days in Part B.
arm group label: Subjects receiving GSK2982772 120 mg TID in cohort 3 : Part B
arm group type: Experimental
description: Eligible subjects will receive GSK2982772 oral capsule with a dose of 120 mg TID for 14 days in Part B.
arm group label: Subjects receiving GSK2982772 240 mg TID in cohort 4: Part B
arm group type: Experimental
description: Eligible subjects will receive GSK2982772 oral capsule with a dose of 240 mg TID for 14 days in Part B.
arm group label: Subjects receiving GSK2982772 360 mg BID in cohort 5: Part B
arm group type: Experimental
description: Eligible subjects will receive GSK2982772 oral capsule with a dose of 360 mg BID for 14 days in Part B.
arm group label: Subjects receiving placebo in cohort 2 : Part B
arm group type: Placebo Comparator
description: Subjects will receive placebo oral capsule for 14 days in Part B.
arm group label: Subjects receiving placebo in cohort 3 : Part B
arm group type: Placebo Comparator
description: Subjects will receive placebo oral capsule for 14 days in Part B.
arm group label: Subjects receiving placebo in cohort 4 : Part B
arm group type: Placebo Comparator
description: Subjects will receive placebo oral capsule for 14 days in Part B.
arm group label: Subjects receiving placebo in cohort 5: Part B
arm group type: Placebo Comparator
description: Subjects will receive placebo oral capsule for 14 days in Part B.
intervention type: Drug
intervention name: GSK2982772 capsule
description: GSK2982772 will be available as size 00, white, opaque capsule containing white to almost white Solid (120 mg maximum fill per capsule). It will be administered orally with water to receive total dose of 120 mg, 240 mg or 360 mg per randomization.
arm group label: Subjects receiving GSK2982772 120 mg TID in cohort 2 : Part B
arm group label: Subjects receiving GSK2982772 120 mg TID in cohort 3 : Part B
arm group label: Subjects receiving GSK2982772 240 mg TID in cohort 4: Part B
arm group label: Subjects receiving GSK2982772 360 mg BID in cohort 5: Part B
arm group label: Subjects receiving treatment sequence ABC in cohort 1: Part A
arm group label: Subjects receiving treatment sequence ABP in cohort 1: Part A
arm group label: Subjects receiving treatment sequence APC in cohort 1: Part A
arm group label: Subjects receiving treatment sequence PBC in cohort 1: Part A
intervention type: Drug
intervention name: Placebo capsule
description: Placebo will be available as size 00, white, opaque capsule containing white to almost white Solid. It will be administered orally with water.
arm group label: Subjects receiving placebo in cohort 2 : Part B
arm group label: Subjects receiving placebo in cohort 3 : Part B
arm group label: Subjects receiving placebo in cohort 4 : Part B
arm group label: Subjects receiving placebo in cohort 5: Part B
arm group label: Subjects receiving treatment sequence ABC in cohort 1: Part A
arm group label: Subjects receiving treatment sequence ABP in cohort 1: Part A
arm group label: Subjects receiving treatment sequence APC in cohort 1: Part A
arm group label: Subjects receiving treatment sequence PBC in cohort 1: Part A
criteria: 
gender: All
minimum age: 18 Years
maximum age: 65 Years
healthy volunteers: Accepts Healthy Volunteers
last name: GSK Clinical Trials
role: Study Director
affiliation: GlaxoSmithKline
facility: 
country: United Kingdom
responsible party type: Sponsor
mesh term: Autoimmune Diseases
provided document: 
provided document: 
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 